A share price of PTC Therapeutics Inc [PTCT] is currently trading at $32.09, up 3.52%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PTCT shares have lost -2.85% over the last week, with a monthly amount glided 1.13%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on May 20, 2024, when Raymond James upgraded its rating to a Mkt Perform. Previously, Morgan Stanley downgraded its rating to Underweight on December 19, 2023, and kept the price target unchanged to $28. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $37 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $165 on October 30, 2023. Citigroup downgraded its rating to a Sell and reduced its price target to $17 on October 27, 2023. Truist downgraded its rating to Hold for this stock on October 06, 2023, and downed its price target to $25. In a note dated September 18, 2023, Citigroup downgraded an Neutral rating on this stock and revised its target price from $55 to $28.
PTC Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $17.53 and $42.14. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $32.09 at the most recent close of the market. An investor can expect a potential return of 37.11% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
Trailing Twelve Months sales for PTC Therapeutics Inc [NASDAQ:PTCT] were 927.56M which represents -4.66% decline. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.4%, Pretax Profit Margin comes in at -0.7%, and Net Profit Margin reading is -0.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 0.78 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.99 points at the first support level, and at 29.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.01, and for the 2nd resistance point, it is at 33.93.
Ratios To Look Out For
To put it in perspective, the Current Ratio for PTC Therapeutics Inc [NASDAQ:PTCT] is 2.03. Also, the Quick Ratio is 1.98, while the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 2.65.
Transactions by insiders
Recent insider trading involved Gravier Pierre, CHIEF FINANCIAL OFFICER, that happened on Jul 16 ’24 when 2269.0 shares were sold. Director, ZELDIS JEROME B completed a deal on May 22 ’24 to sell 20000.0 shares. Meanwhile, EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold 175.0 shares on May 07 ’24.
